Expert Hails NRG1 Fusions as the "Next Big Target" in Oncology

Caroline Seymour
Published: Thursday, Oct 17, 2019
Stephen V. Liu, MD

Stephen Liu, MD

NRG1 fusions occur in low frequency across solid tumors, and because these alterations can evade traditional sequencing modalities, RNA-based next-generation sequencing (NGS) is imperative, said Stephen Liu, MD. Among those in whom these fusions are identified, afatinib (Gilotrif) has shown notable antitumor activity.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication